



TOMÁS J. ARAGÓN, M.D., Dr.P.H.  
Director and State Public Health Officer

State of California—Health and Human Services Agency  
California Department of Public Health



GAVIN NEWSOM  
Governor

Office of AIDS (OA)  
AIDS Drug Assistance Program (ADAP)

Management Memorandum  
Memorandum Number: 2023-06

DATE: April 10, 2023  
TO: ADAP ENROLLMENT WORKERS  
SUBJECT: **ADDITION OF SEXUALLY TRANSMITTED INFECTION (STI) MEDICATIONS TO THE ADAP FORMULARY**

**Effective April 6, 2023**, Podofilox and Tinidazole have been added to the ADAP formulary.

STIs, including trichomoniasis and genital warts, are common but preventable infections. Rapid diagnosis of STIs and access to recommended treatment is critical to improve an individual's health and prevent further STI transmission. As people with HIV can have more severe infection with STIs, the ADAP formulary includes STI treatments that are recommended in the Centers for Disease Control and Prevention (CDC) STI Treatment Guidelines. The [2021 CDC STI Treatment Guidelines](#) include two medications that are not currently on the ADAP formulary - Podofilox and Tinidazole. Podofilox is a topical antiviral that is used to treat genital warts. Tinidazole is an oral antiprotozoal that is used to treat trichomoniasis, giardiasis, amebiasis, and bacterial vaginosis.

The addition of Podofilox and Tinidazole will help modernize the ADAP formulary's options to treat STIs consistent with current national guidelines.

ADAP management requests that you share this information with your clinical leadership team and local prescribers. The [ADAP drug formulary](#) has been updated to reflect the addition of Podofilox and Tinidazole.

If you have any questions regarding the addition of these medications to the ADAP formulary, please contact the OA Formulary Specialist, James Vo ([James.Vo@cdph.ca.gov](mailto:James.Vo@cdph.ca.gov)).

Thank you,

Sharisse Kemp, MSW  
ADAP Branch Chief  
California Department of Public Health